Metsera Shares Leap Premarket as Novo Nordisk Looks to Outbid Pfizer
By Colin Kellaher
Shares of Metsera rose sharply in premarket trading Thursday after Novo Nordisk made an unsolicited proposal to buy the weight-loss drug developer for up to $9 billion, potentially upending Pfizer's agreement to acquire the company.
Novo said it has offered to pay an initial $56.50 a share, or about $6.5 billion, for Metsera, along with contingent value rights worth up to $21.25 a share, bringing the total potential consideration to $77.75 a share.
Pfizer last month agreed to pay an initial $47.50 a share in cash for Metsera, along with up to an additional $22.50 a share tied to milestones that could bring the total consideration to $70 a share, or about $7.3 billion.
Shares of New York-based Metsera, which closed Wednesday at $52.21, were recently up more than 18% at $61.83 in premarket trading.
Novo said its proposal is subject to review by Metsera's board.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 30, 2025 06:36 ET (10:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
Why This Vanguard ETF Is One of the Best
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
United States